Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Navigating the Pharmaceutical Consulting Services Landscape: What to Expect

Jan 22, 2025

Understanding Pharmaceutical Consulting Services

The pharmaceutical industry is a complex and highly regulated sector that requires specialized knowledge and expertise. Pharmaceutical consulting services play a crucial role in helping companies navigate this intricate landscape. From regulatory compliance to market access strategies, these services offer essential support to ensure the success and sustainability of pharmaceutical businesses.

Consultants in this field bring a wealth of experience and knowledge, often having worked in various roles within the industry. They provide insights and guidance on a range of topics, helping companies to streamline processes, enhance efficiency, and ultimately deliver better outcomes for patients.

pharmaceutical consulting

Regulatory Compliance and Strategy

One of the primary areas where pharmaceutical consultants provide value is in regulatory compliance. Given the stringent regulations governing pharmaceuticals, ensuring compliance is a top priority for any company in this field. Consultants assist in understanding and navigating the complex web of regulations at both the national and international levels.

They help companies develop strategies to meet these regulatory requirements while minimizing risks and avoiding potential pitfalls. This can include everything from preparing submissions for regulatory approval to conducting audits and providing training on compliance best practices.

regulatory compliance

Market Access and Commercialization

Successfully bringing a new drug to market involves more than just obtaining regulatory approval. Pharmaceutical consultants also help companies with market access strategies, ensuring that new products reach the right markets efficiently and effectively. This includes pricing strategies, reimbursement planning, and stakeholder engagement.

Consultants often have deep insights into healthcare systems and payer landscapes, which they leverage to tailor strategies that meet the unique needs of each market. This expertise is particularly valuable in navigating the diverse healthcare environments across different countries.

market strategy

Research and Development Optimization

In the competitive pharmaceutical industry, optimizing research and development (R&D) processes is crucial for staying ahead. Consultants can help identify inefficiencies in R&D workflows and suggest improvements that enhance productivity and reduce time-to-market for new drugs.

They provide guidance on best practices for clinical trials, data management, and innovative technologies that can accelerate the R&D process. By leveraging their expertise, companies can ensure that their R&D efforts are not only effective but also aligned with current industry trends and future demands.

Challenges and Considerations

While pharmaceutical consulting services offer numerous benefits, there are challenges to consider. Engaging with consultants requires clear communication of objectives and expectations. Companies must also carefully evaluate the expertise and track record of potential consulting partners to ensure they align with their specific needs.

Another consideration is the cost of consultancy services. While these services represent an investment, their impact on business outcomes can be significant. Companies should weigh the potential return on investment against the initial costs when deciding to engage with consultants.

consulting challenges

The Future of Pharmaceutical Consulting

As the pharmaceutical industry continues to evolve, so too will the role of consulting services. With advancements in digital health technologies, personalized medicine, and artificial intelligence, consultants will need to adapt and expand their expertise to address these emerging trends.

The future of pharmaceutical consulting promises exciting opportunities for companies willing to embrace innovation. By partnering with the right consultants, businesses can navigate the ever-changing landscape and remain competitive in this dynamic industry.